The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Eloxatin 5 mg/ml Concentrate for Solution for Infusion



Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/148/001

Main Information

Trade NameEloxatin 5 mg/ml Concentrate for Solution for Infusion
Active SubstancesOxaliplatin
Dosage FormConcentrate for solution for infusion
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/148/001

Group Information

ATC CodeL01XA Platinum compounds
L01XA03 oxaliplatin

Status

License statusWithdrawn
Withdrawn Date18/04/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back